{
  "http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1211" : {
    "http://www4.wiwiss.fu-berlin.de/dailymed/resource/dailymed/indication" : [ {
      "value" : "50% Dextrose Injection is indicated in the treatment of insulin\nhypoglycemia (hyperinsulinemia or insulin shock) to restore blood glucose\nlevels. The solution is also indicated, after dilution,\nfor intravenous infusion as a source of carbohydrate calories in patients\nwhose oral intake is restricted or inadequate to maintain nutritional requirements.\nSlow infusion of hypertonic solutions is essential to insure proper utilization\nof dextrose and avoid production of hyperglycemia.",
      "type" : "literal"
    } ],
    "http://www4.wiwiss.fu-berlin.de/dailymed/resource/dailymed/genericMedicine" : [ {
      "value" : "Dextrose",
      "type" : "literal"
    } ],
    "http://www4.wiwiss.fu-berlin.de/dailymed/resource/dailymed/supply" : [ {
      "value" : "50% Dextrose Injection, USP is supplied in single-dose containers\nas follows: Exposure of pharmaceutical products to heat should be minimized.\nAvoid excessive heat. Protect from freezing. It is recommended that the product\nbe stored at room temperature (25��C); however, brief exposure up to 40��C\ndoes not adversely affect the product. HOSPIRA, INC., LAKE FOREST,\nIL 60045 USA Abboject is\na trademark of the Abbott group of companies.",
      "type" : "literal"
    } ],
    "http://www4.wiwiss.fu-berlin.de/dailymed/resource/dailymed/fullName" : [ {
      "value" : "Dextrose (Injection, Solution)",
      "type" : "literal"
    } ],
    "http://www4.wiwiss.fu-berlin.de/dailymed/resource/dailymed/clinicalPharmacology" : [ {
      "value" : "When administered intravenously this solution restores blood\nglucose levels in hypoglycemia and provides a source of carbohydrate calories. Carbohydrate\nin the form of dextrose may aid in minimizing liver glycogen depletion and\nexerts a protein-sparing action. Dextrose injection undergoes oxidation to\ncarbon dioxide and water. Water is an essential constituent\nof all body tissues and accounts for approximately 70% of total body weight.\nAverage normal adult requirement ranges from two to three liters (1.0 to 1.5\nliters each for insensible water loss by perspiration and urine production). Water\nbalance is maintained by various regulatory mechanisms. Water distribution\ndepends primarily on the concentration of electrolytes in the body compartments\nand sodium (Na) plays a major role in maintaining physiologic\nequilibrium.",
      "type" : "literal"
    } ],
    "http://www4.wiwiss.fu-berlin.de/dailymed/resource/dailymed/warning" : [ {
      "value" : "50% Dextrose Injection is hypertonic and may cause phlebitis\nand thrombosis at the site of injection. Significant\nhyperglycemia and possible hyperosmolar syndrome may result from too rapid\nadministration. The physician should be aware of the symptoms of hyperosmolar\nsyndrome, such as mental confusion and loss of consciousness, especially in\npatients with chronic uremia and those with known carbohydrate intolerance. The\nintravenous administration of this solution can cause fluid and/or solute\noverloading resulting in dilution of serum electrolyte concentrations, overhydration,\ncongested states or pulmonary edema. Additives may be\nincompatible. Consult with pharmacist if available. When introducing additives,\nuse aseptic technique, mix thoroughly and do not store. For peripheral vein administration: The\nsolution should be given slowly, preferably through a small bore needle into\na large vein, to minimize venous irritation. For central venous administration: Concentrated\ndextrose should be administered via central vein only after suitable dilution.",
      "type" : "literal"
    } ],
    "http://www.w3.org/2000/01/rdf-schema#label" : [ {
      "value" : "Dextrose (Injection, Solution)",
      "type" : "literal"
    } ],
    "http://www4.wiwiss.fu-berlin.de/dailymed/resource/dailymed/activeIngredient" : [ {
      "value" : "http://www4.wiwiss.fu-berlin.de/dailymed/resource/ingredient/Dextrose_Hydrous",
      "type" : "uri"
    } ],
    "http://www4.wiwiss.fu-berlin.de/dailymed/resource/dailymed/dosage" : [ {
      "value" : "For peripheral vein administration: Injection of the solution should be made slowly. The maximum rate\nat which dextrose can be infused without producing glycosuria is 0.5 g/kg\nof body weight/hour. About 95% of the dextrose is retained when infused ata rate of 0.8 g/kg/hr. In insulin-induced hypoglycemia,\nintravenous injection of 10 to 25 grams of dextrose (20 to 50 mL of 50%\ndextrose) is usually adequate. Repeated doses and supportive treatment may\nbe required in severe cases. A specimen for blood glucose determination should\nbe taken before injecting the dextrose. In such emergencies, dextrose should\nbe administered promptly without awaiting pretreatment test results. For central venous administration: For\ntotal parenteral nutrition 50% Dextrose Injection, USP is administered by\nslow intravenous infusion (a) after admixture with amino acid solutions via\nan indwelling catheter with the tip positioned in a large central vein, preferably\nthe superior vena cava, or (b) after dilution with sterile water for injection.\nDosage should be adjusted to meet individual patient requirements. Clinical\nevaluation and periodic laboratory determinations are necessary to monitor\nchanges in fluid balance, electrolyte concentrations and acid-base balance\nduring prolonged parenteral therapy or whenever the condition of the patient\nwarrants such evaluation. The maximum rate of dextrose\nadministration which does not result in glycosuria is the same as cited above. Parenteral\ndrug products should be inspected visually for particulate matter and discoloration\nprior to administration, whenever solution and container permit. See CONTRAINDICATIONS.",
      "type" : "literal"
    } ],
    "http://www4.wiwiss.fu-berlin.de/dailymed/resource/dailymed/inactiveIngredient" : [ {
      "value" : "http://www4.wiwiss.fu-berlin.de/dailymed/resource/ingredient/Water",
      "type" : "uri"
    }, {
      "value" : "http://www4.wiwiss.fu-berlin.de/dailymed/resource/ingredient/Hydrochloric_Acid",
      "type" : "uri"
    }, {
      "value" : "http://www4.wiwiss.fu-berlin.de/dailymed/resource/ingredient/Sodium_Hydroxide",
      "type" : "uri"
    } ],
    "http://www4.wiwiss.fu-berlin.de/dailymed/resource/dailymed/name" : [ {
      "value" : "Dextrose",
      "type" : "literal"
    } ],
    "http://www4.wiwiss.fu-berlin.de/dailymed/resource/dailymed/routeOfAdministration" : [ {
      "value" : "http://www4.wiwiss.fu-berlin.de/dailymed/resource/routeOfAdministration/Intravenous",
      "type" : "uri"
    } ],
    "http://www4.wiwiss.fu-berlin.de/dailymed/resource/dailymed/activeMoiety" : [ {
      "value" : "http://www4.wiwiss.fu-berlin.de/dailymed/resource/ingredient/Dextrose",
      "type" : "uri"
    } ],
    "http://www4.wiwiss.fu-berlin.de/dailymed/resource/dailymed/representedOrganization" : [ {
      "value" : "http://www4.wiwiss.fu-berlin.de/dailymed/resource/organization/Hospira%2C_Inc.",
      "type" : "uri"
    } ],
    "http://www4.wiwiss.fu-berlin.de/dailymed/resource/dailymed/adverseReaction" : [ {
      "value" : "Hyperosmolar syndrome, resulting from excessively rapid administration\nof concentrated dextrose may cause mental confusion and/or loss of consciousness. Reactions\nwhich may occur because of the solution or the technique of administration\ninclude febrile response, infection at the site of injection, venous thrombosis\nor phlebitis extending from the site of injection, extravasation and hypervolemia. If\nan adverse reaction does occur, discontinue the infusion, evaluate the patient,\ninstitute appropriate therapeutic countermeasures and save the remainder of\nthe fluid for examination if deemed necessary.",
      "type" : "literal"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ {
      "value" : "http://www4.wiwiss.fu-berlin.de/drugbank/vocab/resource/class/Offer",
      "type" : "uri"
    }, {
      "value" : "http://www4.wiwiss.fu-berlin.de/dailymed/resource/dailymed/drugs",
      "type" : "uri"
    } ],
    "http://www4.wiwiss.fu-berlin.de/dailymed/resource/dailymed/contraindication" : [ {
      "value" : "A concentrated dextrose solution should not be used when\nintracranial or intraspinal hemorrhage is present, nor in the presence of\ndelirium tremens if the patient is already dehydrated. Dextrose\ninjection without electrolytes should not be administered simultaneously with\nblood through the same infusion set because of the possibility that pseudoagglutination\nof red cells may occur.",
      "type" : "literal"
    } ],
    "http://www4.wiwiss.fu-berlin.de/dailymed/resource/dailymed/precaution" : [ {
      "value" : "Do not use unless the solution is clear and seal is intact.\nDiscard unused portion. Electrolyte deficits, particularly\nin serum potassium and phosphate, may occur during prolonged use of concentrated\ndextrose solutions. Blood electrolyte monitoring is essential and fluid and\nelectrolyte imbalances should be corrected. Essential vitamins and minerals\nalso should be provided as needed. To minimize hyperglycemia\nand consequent glycosuria, it is desirable to monitor blood and urine glucose\nand if necessary, add insulin. When a concentrated dextrose\ninfusion is abruptly withdrawn, it is advisable to follow with the administration\nof 5% or 10% dextrose injection to avoid rebound hypoglycemia. Solutions\ncontaining dextrose should be used with caution in patients with known subclinical\nor overt diabetes mellitus. Care should be exercised\nto insure that the needle is well within the lumen of the vein and that extravasation\ndoes not occur. If thrombosis should occur during administration, the injection\nshould be stopped and corrective measures instituted. Concentrated\ndextrose solutions should not be administered subcutaneously or intramuscularly.<br/>Carcinogenesis, Mutagenesis, Impairment of Fertility:: Studies with solutions in polypropylene syringes have not\nbeen performed to evaluate carcinogenic potential, mutagenic potential or\neffects on fertility.<br/>Pregnancy Category C.: Animal reproduction studies have not been conducted with\ndextrose. It is also not known whether dextrose can cause fetal harm when\nadministered to a pregnant woman or can affect reproduction capacity. Dextrose\nshould be given to a pregnant woman only if clearly needed.<br/>Nursing Mothers: It is not known whether this drug is excreted in human milk.\nBecause many drugs are excreted in human milk, caution should be exercised\nwhen 50% Dextrose Injection, USP is administered to a nursing mother.",
      "type" : "literal"
    } ],
    "http://www4.wiwiss.fu-berlin.de/dailymed/resource/dailymed/description" : [ {
      "value" : "50% Dextrose Injection, USP is a sterile, nonpyrogenic, hypertonic\nsolution of dextrose in water for injection for intravenous injection as a\nfluid and nutrient replenisher. Each mL of fluid contains\n0.5 g dextrose, hydrous which delivers 3.4 kcal/gram. The solution has an\nosmolarity of 2.53 mOsmol/mL (calc.), a pH of 4.2 (3.2 to 6.5) and may contain\nsodium hydroxide and/or hydrochloric acid for pH adjustment. The\nsolution contains no bacteriostat, antimicrobial agent or added buffer (except\nfor pH adjustment) and is intended only for use as a single-dose injection.\nWhen smaller doses are required, the unused portion should be discarded with\nthe entire unit. Dextrose, USP is chemically designated\nCHO���HO (D-glucose\nmonohydrate), a hexose sugar freely soluble in water. Dextrose, hydrous has\nthe following structural formula: Water\nfor Injection, USP is chemically designated HO . The\nsyringe is molded from a specially formulated polypropylene. Water permeates\nfrom inside the container at an extremely slow rate which will have an insignificant\neffect on solution concentration over the expected shelf life. Solutions in\ncontact with the plastic container may leach out certain chemical components\nfrom the plastic in very small amounts; however, biological testing was supportive\nof the safety of the syringe material.",
      "type" : "literal"
    } ],
    "http://www4.wiwiss.fu-berlin.de/dailymed/resource/dailymed/overdosage" : [ {
      "value" : "In the event of overhydration or solute overload during therapy,\nre-evaluate the patient and institute appropriate corrective measures. See\nWARNINGS and PRECAUTIONS.",
      "type" : "literal"
    } ]
  }
} {
  "http://www4.wiwiss.fu-berlin.de/dailymed/resource/organization/Hospira,_Inc." : {
    "http://www4.wiwiss.fu-berlin.de/dailymed/resource/dailymed/producesDrug" : [ {
      "value" : "http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1211",
      "type" : "uri"
    } ]
  }
}